Redesigned Device Provides Surgeons with Ease of Use While Ensuring Quality Patient Care
Amedica Corporation, a biomaterial company, today announced the launch of its new Silicon Nitride Anterior Lumbar (AL) Interbody Fusion Device. The Valeo II AL Interbody Fusion Device includes enhancements that contribute to improved surgeon ease of use and quality patient care.
The Valeo II AL provides a new design that offers enhanced bone-to-implant interface and resistance to push out when compared to competitive offerings. The Valeo II AL is made out of Amedica’s Silicon Nitride biomaterial which has been shown to help promote bone growth and also has anti-infective properties. Valeo II AL Silicon Nitride Interbody Fusion Devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT. The combination of these properties is only found in Amedica’s Silicon Nitride biomaterial technology.
“Amedica is committed to delivering products that address the changing needs of spinal surgeons. Our next generation Silicon Nitride AL device provides an optimal environment for bone growth while reducing the risk for infection due to its innate anti-infective properties. These benefits have the potential to improve the efficacy of spinal fusion procedures resulting in enhanced patient care,” said Eric K. Olson, President and Chief Executive Officer, Amedica. “As Amedica continues to collaborate with surgeons to develop innovative, safe and effective interbody fusion devices, Silicon Nitride is increasingly becoming the gold standard material for spinal fusion devices. With the launch of Valeo II AL, Amedica is positioned to rapidly increase our market share in the $1.6B interbody fusion device market.”
The Valeo II AL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion.
